<DOC>
	<DOCNO>NCT00031018</DOCNO>
	<brief_summary>In phase I-II parallel design , randomize , double-blind clinical trial determine 3,000 30,000 unit ingest hrIFN-a prevents deterioration cognitive functioning patient dementia Alzheimer 's type ( AD ) whether ingest hrIFN-a treatment decrease acute phase reactant pro-inflammatory cytokine IL-6 mild moderate AD . We predict novel anti-inflammatory agent ingest human recombinant interferon alpha ( hrIFN-a ) modulate inflammation inhibit natural history AD progression . If eligible , receive Aricept 5 week ( donezepil ) thereafter addition Aricept either placebo ( inactive substance ) interferon alpha 3,000 30,000 unit every day 12 month .</brief_summary>
	<brief_title>Prevention Cognitive Decline Alzheimer 's Disease Ingested Interferon Alpha</brief_title>
	<detailed_description>Inflammatory mechanism contribute neurodegeneration AD . Acute phase proteins antichymotrypsin ( a1ACT ) , pro-inflammatory cytokine IL-6 IL-1 , activate microglial cell associate neuritic plaque . a1ACT level elevate AD , correlate cognitive decline serve biological marker intervention . a1ACT intimately associate 42-AA b peptide ( Ab ) filamentous amyloid deposit stimulate polymerization Ab amyloid filament . IL-6 find AD cortex prior onset neuritic change , serum stimulate PMNC IL-6 level higher AD , may induce b-amyloid protein deposition . Microglia , CNS resident inflammatory cell , produce IL-6 within adult human brain , IL-1a + , prominent component neuritic plaque . Because pathogenesis AD appear part immune mediate , propose test directly humans whether ingested IFN-a ameliorate AD . Because good model inflammation animal model AD , directly determine human 1 ) 3,000 30,000 IU hrIFN-a inhibits natural history rate cognitive decline mild moderate AD use neuropsychological instrument primary secondary outcome measure 2 ) correlate inhibition acute phase reactant pro-inflammatory IL-6 . If novel anti-inflammatory agent inhibits natural history rate cognitive decline AD pilot phase II trial , would provide preliminary data submit phase III clinical trial . IFNs administer oral route show systemic effect . Oral IFN-a cause neutropenia mouse . In contrast i.p . administration , oral IFN-a result presence detectable level IFNs blood . Circulating specific antibody IFN block neutropenic effect i.p . IFN , block neutropenic effect oral IFNs ( 2 ) . Therefore , examine expression antiviral MxA message , type 1 IFN-specific induced signal , sensitive marker type 1 IFN interaction lymphoid cell gut-associated lymphoid tissue ( GALT ) use semi-quantitative RT-PCR splenocytes mice PMNC man IFN-a ingestion . Both mice man demonstrate inducible level Mx mRNA ingest IFN-a . Murine spleen T cell CD8+ T cell also demonstrate upregulation Mx mRNA . Therefore , ingest IFN-a act via establish pathway type 1 IFN signalling ( 3 ) . Elevated level activate T cell , mainly CD8+ ( cytotoxic/suppressor ) phenotype , find AD brain contact microglial cell ( 4 ) . Interestingly , peripheral CD8+ T cell deplete AD patient ( 5 ) . Lymphocytes bear T helper T cytotoxic/suppressor cell antigens find hippocampus temporal cortex AD ( 6,7 ) . The data suggest lymphocytes part inflammation AD , potential immunomodulatory T CD8+ T cell contact ingest non-absorbed IFN GALT could migrate brain decrease inflammation .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memory Disorders</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Males female , age 50 great . Possible probable dementia Alzheimer Type define NINDSARDA criterion dementia least one year duration . Folstein MMSE Score 1024 inclusive . Vision , hearing , speech , motor function comprehension must adequate compliance test procedure . Absence reliable caregiver . Clinical radiological evidence neurological disorder Parkinson 's disease , normal pressure hydrocephalus , multiinfarct dementia , idiopathic seizure disorder , CNS infectious disease . History major psychiatric disorder ; schizophrenia unipolar bipolar depression . Presence significant medical disorder might cause contribute dementia B12 folic acid deficiency , untreated hypothyroidism , history significant alcohol abuse ( within past 10 year ) . Patients recent ( &lt; 2 year ) hematologic/oncologic disorder ( basal squamous cell carcinoma skin . Patients recent ( &lt; 3 month ) myocardial infarction , poorly control CHF , surgery peripheral vascular disease , coronary artery bypass surgery . Evidence clinically significant unstable active GI , hepatic pulmonary disease . History document stroke one confirm TIA . Any condition would make patient caregiver , opinion principal investigator unsuitable study . Patients know hypersensitivity Donezepil HCL piperidine contain drug .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>immunosenescence</keyword>
	<keyword>autoimmunity</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>pro-inflammatory cytokine</keyword>
	<keyword>Hayflick phenomenon</keyword>
</DOC>